Apr. 26, 2018 - "As I have indicated previously, the improved US market access delivered strong growth and Zubsolv® broke its volume record"
APRIL 26 2018 In Q118 Zubsolv broke its volume record and delivered a revenue growth of 26 percent in USD. Two new early-stage projects lead to an update of the the pipeline. The financial position continued to improve, fueled by yet another strong cash-generating quarter.
On Thursday, April 26 at 8.00 am CET the Q118 report will get announced. The same day at 3.00 pm, analysts, investors and media are invited to attend an audiocast where CEO, Nikolaj Sørensen, and CFO, Henrik Juuel, will present the report. To attend please view link below.
Opioid abuse is today the most common cause of death from drug overdose. The problem is greatest in the US, where just over 60,000 Americans died of an overdose in 2016, mainly caused by use of opioids. Orexo’s key market is the US market for the treatment of opioid dependence.